Apixaban Tablet, Film Coated
Product Images NDC 33342-337

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Apixaban (NDC 33342-337). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

889 (Apixaban 2 5mg 100s Carton)

The image shows the packaging label for Apixaban Tablets 2.5 mg by Macleods Pharmaceuticals Limited. It includes the product name, strength (2.5 mg), dosage form as film-coated tablets, and indicates a package size of 100 tablets (10 x 10 unit-dose). The label mentions the product is for oral use and includes storage instructions and manufacturer details.*

FDA Label Image

112 (Apixaban 2 5mg 500s Container)

Apixaban 2.5 mg film-coated tablets label from Macleods Pharmaceuticals Limited. The label indicates oral tablets with each containing 2.5 mg apixaban, packaged as 500 tablets. Storage instructions are detailed, with a caution not to use the product if the inner seal is broken or missing. The label includes manufacturer and distributor addresses in the USA and India, plus a pharmacist dispensing note.*

FDA Label Image

009 (Apixaban 2 5mg 60s Container)

Apixaban 2.5 mg film-coated tablets label from Macleods Pharmaceuticals Limited. The label states the dosage strength of 2.5 mg per tablet and provides storage instructions. It includes manufacturer details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd, India. The package contains 60 tablets.*

FDA Label Image

009 (Apixaban 5mg 100s Carton)

Packaging label for Apixaban Tablets, 5 mg strength, film-coated oral tablets. The label indicates 100 tablets (10 x 10 unit-dose) per package. Manufactured by Macleods Pharmaceuticals Ltd, distributed by Macleods Pharma USA, Inc. The label includes storage instructions and a note that the unit-dose package is not child-resistant.*

FDA Label Image

897 (Apixaban 5mg 500s Container)

Label for Apixaban Tablets 5 mg film-coated oral tablets by Macleods Pharmaceuticals Limited. The label includes dosage storage instructions, pharmacist dispensing guidance, and states the package contains 500 tablets. Manufactured for Macleods Pharma USA, Inc. in Princeton, NJ, and Macleods Pharmaceuticals Ltd. in India.*

FDA Label Image

343 (Apixaban 5mg 60s Container)

Label for Apixaban Tablets 5 mg, film-coated oral tablets. The label states each tablet contains 5 mg apixaban, with a package count of 60 tablets. It is manufactured by Macleods Pharmaceuticals Limited and distributed by Macleods Pharma USA, Inc. Storage instructions and a pharmacist dispensing note are also visible.*

FDA Label Image

Fig-4 (Apixaban Figure 4)

A Kaplan-Meier curve showing the proportion of subjects with stroke or systemic embolism over 36 months, comparing Apixaban and Warfarin treatments. The graph includes the number of subjects at risk at various time points and reports event counts and hazard ratio for Apixaban versus Warfarin.*

FDA Label Image

Figure-1 (Apixaban Figure 1)

A forest plot comparing hazard ratios with 95% confidence intervals for various subgroups of patients receiving Apixaban versus Warfarin. The plot displays hazard ratios for categories such as prior Warfarin use, age, sex, weight, prior stroke or TIA, diabetes mellitus, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization, with markers indicating point estimates and confidence intervals about the line of no effect (hazard ratio = 1).*

FDA Label Image

Fig-2 (Apixaban Figure 2)

A scatter plot chart depicting the fold change and 90% confidence interval in pharmacokinetic parameters (Cmax and AUC) of Apixaban when co-administered with various interacting drugs including strong CYP3A4 and P-gp inhibitor Ketoconazole 400 mg, other CYP3A4 and P-gp inhibitors Diltiazem 360 mg and Naproxen 500 mg, and strong CYP3A4 and P-gp inducer Rifampin 600 mg. The x-axis shows change relative to reference, ranging from 0.5 to 2.0.*

FDA Label Image

Fig-3 (Apixaban Figure 3)

A chart showing pharmacokinetic fold change with 90% confidence intervals for different populations relative to a reference. It includes categories such as various degrees of renal impairment, age groups, body weight ranges, and hepatic impairment, with corresponding recommendations on dose adjustments for Apixaban.*

FDA Label Image

Fig-5 (Apixaban Figure 5)

A forest plot chart showing subgroups of patients comparing the number of events and hazard ratios between Apixaban and Warfarin. It includes demographic and clinical variables such as prior Warfarin use, age, sex, weight, stroke history, diabetes status, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization. The plot visually displays hazard ratios with confidence intervals for each subgroup, indicating comparative effectiveness between Apixaban and Warfarin.*

FDA Label Image

Str (Apixaban Structure)

Chemical structure of Apixaban, showing its molecular framework including key functional groups and rings characteristic of the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.